Seattle Genetics, Inc. (SGEN), Celldex Therapeutics, Inc. (CLDX): This Company Has Potential to Grow

Page 2 of 2

Final assessment

I would say that these cancer treatments are in demand right now and would remain in demand in the future considering the prevalence of cancer among patients in the U.S. Thus, Seattle Genetics should perform well in the future. As for ImmunoGen, Inc. (NASDAQ:IMGN) and Celldex, they are smaller than Seattle on the basis of market cap, but they too are poised for growth because of the demand for their drugs.

usman iftikhar has no position in any stocks mentioned. The Motley Fool recommends ImmunoGen and Seattle Genetics.

The article This Company Has Potential to Grow originally appeared on Fool.com and is written by usman iftikhar.

usman is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2